Iron, Expression of the Pattern Recognition Receptor-Inflammasome System, and Early Death in Adults with Sickle Cell Disease

Rationale Patients with sickle cell disease (SCD) are marked by chronic inflammation but the cause of this inflammation and the relevance to patient survival are unknown. Objective To assess the relationship between iron, inflammation and early death in SCD. Methods and Results Using peripheral blood mononuclear cell transcriptome profile hierarchical clustering, we classified 24 patients and 10 controls in clusters with significantly different expression of genes known to be regulated by iron. Subsequent gene set enrichment analysis showed that many genes associated with the high iron cluster were involved in innate immunity pattern recognition receptor (PRR) pathways. These included Toll-like receptors TLR4, TLR7 and TLR8; NOD-like receptors NLRP3 and NLRC4; C-type lectin receptor CLEC7A/Dectin-1; humoral pattern recognition receptor pentraxin-3, the common inflammasome effector caspase-1 and one of its substrates, IL-18. Quantitative PCR confirmed quantitative expression of several representative genes and showed that ferritin light chain, TLR4 and interleukin-6 mRNAs were expressed over 100-fold more highly in SCD patients than in controls (P0.8 mg/dL) had the highest mortality, and those with the lowest level (CRP Conclusions The SCD PBMC transcriptome reflects high intracellular iron exposure, which is associated with inflammation and mortality. The associations found in this study support a hypothetical model in which high intracellular iron in macrophages promotes clinically significant inflammatory pathways involving pattern recognition receptors and innate immune function, identifying potential targets for pharmacological intervention with drugs already approved for inflammasome-mediated disorders. Figure 1 Figure 1. Figure. Kaplan Meier curve showing a significant difference in survival between patients with low and high CRP. SCD Patients (n=412) of the NIH pulmonary hypertension screening cohort (ClinicalTrials.gov identifier: NCT00011648) Patients were divided in high, intermediate and low CRP groups. Kaplan-Meier survival curves show that mortality rate significantly increased according to CRP group.(P=0.0017).Five year mortality percentages for the low, intermediate and high CRP groups were respectively 12.4%, 20.5 and 25.8%. In a multivariate analysis, CRP was an independent predictor of mortality. Disclosures van Beers: Novartis: Research Funding.